Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mallinckrodt Looks To Increase Hospital Product Offerings With Questcor Purchase

This article was originally published in The Pink Sheet Daily

Executive Summary

Less than a year after its spinout, Mallinckrodt has announced its second large acquisition, paying $5.6 billion for Questcor and its potential blockbuster product.

You may also be interested in...



Why Is Congress Targeting These Six Medicines In Drug Price Hearing?

Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.

The ‘Re-Pricer’ Reckoning: Makena, Daraprim And Acthar Under Pressure

The controversies have shown that, while it may be easy to scapegoat outliers, it is remarkably hard to lower a drug price by political fiat. It took a while, but now Makena, Daraprim and Acthar are all facing very different days of reckoning.

Payer Pushback Underpins Mallinckrodt's Disappointing Q3 Results

Mallinckrodt's high-priced H.P Acthar Gel was under pressure in the third quarter, which management attributed to payer complexities. The issue is broader than just Acthar, firm says.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS077173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel